LEADER 05394nam 22007215 450 001 9910300086003321 005 20200704020252.0 010 $a1-4939-0515-5 024 7 $a10.1007/978-1-4939-0515-7 035 $a(CKB)2560000000148297 035 $a(EBL)1698089 035 $a(OCoLC)877944573 035 $a(SSID)ssj0001204876 035 $a(PQKBManifestationID)11798928 035 $a(PQKBTitleCode)TC0001204876 035 $a(PQKBWorkID)11180467 035 $a(PQKB)10288542 035 $a(MiAaPQ)EBC1698089 035 $a(DE-He213)978-1-4939-0515-7 035 $a(PPN)178317284 035 $a(EXLCZ)992560000000148297 100 $a20140411d2014 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aDyslipidemias in Kidney Disease /$fedited by Adrian Covic, Mehmet Kanbay, Edgar V. Lerma 205 $a1st ed. 2014. 210 1$aNew York, NY :$cSpringer New York :$cImprint: Springer,$d2014. 215 $a1 online resource (325 p.) 300 $aDescription based upon print version of record. 311 $a1-4939-0514-7 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $a"" Atherogenic Dyslipidemia in CKD: Enhanced Disease Progression""""Renal Injury""; "" Vascular Injury""; "" Renal Pathophysiological Changes Driven by Atherogenic Dyslipidemia""; ""Oxidative Stress""; "" Endoplasmic Reticulum Stress""; "" Inflammatory Stress""; "" Mesangial Cell Proliferation and Matrix Expansion""; "" Inflammatory Stress Modifies Lipid Homeostasis""; ""Inflammation Changes Lipid Composition""; "" Inflammation Causes Cholesterol Redistribution""; "" The Impact of Statins on CKD""; ""Effect of Statins on Renal Protection: Evidence from CVD Trial"" 327 $a"" Effect of Statins on Renal Protection: Evidence from CKD Trials"""" The Pleiotropic Effects of Statins""; "" Statin Resistance Under Inflammatory Stress""; "" How Long a Low LDL Cholesterol Status Should be Maintained?""; "" Conclusion""; ""References""; ""Chapter 3: Hyperlipidemia as a Risk Factor for Progression of CKD in Nondiabetics""; ""Introduction""; "" Lipid Abnormalities Secondary to CKD""; "" Pathogenesis of Kidney Injury due to Dyslipidemia""; "" Lipid Abnormalities and Progression of CKD""; "" Conclusion""; ""References"" 327 $a""Chapter 4: How Lipid-Lowering Agents Work: The Good, the Bad, and the Ugly""""Introduction""; "" Statins""; ""Mechanism of Action""; "" Effects of Statins""; "" Statins in Predialysis CKD Patients""; "" CKD Progression""; "" Proteinuria""; ""Statins in Dialysis Patients""; "" Satins in Renal Transplant Patients""; "" Tolerability and Safety of Statins""; "" Fibric Acid Derivatives""; ""Mechanism of Action""; "" Effects of Fibrates""; "" Tolerability and Safety of Fibrates""; "" Cholesterol Absorption Inhibitors""; ""Mechanism of Action""; "" Effects of Ezetimibe"" 327 $a"" Tolerability and Safety of Ezetimibe"""" Nicotinic Acid""; ""Mechanism of Action""; "" Effects of Niacin""; "" Tolerability and Safety of Niacin""; "" Bile Acid Sequestrants""; ""Mechanism of Action""; "" Effect of Bile Acid Sequestrants""; "" Tolerability and Safety of Bile Acid Sequestrants""; "" Conclusion""; ""References""; ""Chapter 5: CVD in CKD: Focus on the Dyslipidemia Problem""; ""Introduction""; "" Definition and Classification of CKD""; "" Association Between CKD and CVD-Epidemiological Data""; ""In the General Population"" 327 $a"" In Patients with CV Risk Factors or Preexistent CVD"" 330 $aDyslipidemia in chronic kidney disease is a common clinical problem and growing in prevalence.  With the recent publication of clinical practice guidelines on the management of lipid related disorders in patients affected by chronic kidney disease, an up-to-date and comprehensive resource of evidence-based literature is needed. Dyslipidemias in Kidney Disease captures the growing body of information on this subject matter. This book presents the latest clinical evidence and management guidance for patients of various demographics and stages of chronic kidney disease.  Written for the nephrologist community, as well as cardiologists and general practitioners, this guide will provide practical knowledge and fill a much needed void in the literature.  . 606 $aNephrology 606 $aCardiology 606 $aInternal medicine 606 $aNephrology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33126 606 $aCardiology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33037 606 $aInternal Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H33002 615 0$aNephrology. 615 0$aCardiology. 615 0$aInternal medicine. 615 14$aNephrology. 615 24$aCardiology. 615 24$aInternal Medicine. 676 $a610 676 $a616 676 $a616.12 676 $a616.61 702 $aCovic$b Adrian$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aKanbay$b Mehmet$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aLerma$b Edgar V$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910300086003321 996 $aDyslipidemias in Kidney Disease$91522986 997 $aUNINA